
Prenetics: Strong Liquidity And Rapidly Rising Revenue
Prenetics: Strong Liquidity And Rapidly Rising Revenue
Loading news...

Prenetics: Strong Liquidity And Rapidly Rising Revenue

Prenetics Global (NASDAQ: PRE - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Institutional and Insider Ownership 25.0% of Prenetics

Prenetics Global Limited is rated a buy, with a projected 150% upside based on forward EV/S and robust revenue growth from IM8. PRE has been working to reduce its direct costs, with a sequential improvement of 9% (QoQ) while increasing IM8's gross margin by 8 percentage points on a sequential basis. My calculation shows that Prenetics Global has a cash runway of about 18 months with a net burn rate of about $25 million in nine months.

Prenetics Global (PRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Talk about an about-face. What Prenetics Global once a called a long-term, “unprecedented commitment” to bitcoin has gone by the wayside in just six months.

CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has entered into warrant exchange agreements, subject to customary closing conditions, with holders representing approximately 83.4% of its outstanding Class A and Class B warrants, pursuant to a voluntary warrant exchange program designed to simplify the Company's capital structure and materially reduce potential future dilution.

Prenetics Global Limited (NASDAQ: PRE - Get Free Report) shares were up 3.2% during trading on Thursday. The stock traded as high as $16.97 and last traded at $16.49. Approximately 170,202 shares traded hands during trading, an increase of 25% from the average daily volume of 136,406 shares. The stock had previously closed at $15.98.

Does Prenetics Global Limited (PRE) have what it takes to be a top stock pick for momentum investors? Let's find out.

CHARLOTTE, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced its participation in the following upcoming investor conferences.

CHARLOTTE, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8 and a global health-tech and longevity company pioneering a dual-engine strategy across consumer wellness and Bitcoin, today announced that all key members of its executive leadership team have executed open market purchases of Prenetics' common stock during the Company's designated trading window.

H&M CELEBRATES OPENING WITH AMELIA GRAY, DELILAH BELLE, JULEZ SMITH, AND TINA KNOWLES LOS ANGELES , Nov. 20, 2025 /PRNewswire/ -- Today, H&M opened its first-ever location in Beverly Hills at 370 North Beverly Drive. This special destination store focuses on offering the most fashion-forward womenswear through a handpicked curation of H&M's most elevated designs, special collections, accessories, and H&M Pre-Loved.

IM8's Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial Position Cantor Forecasts $217 Million in FY2026 Revenue as IM8 Expands Internationally and Sharpens Strategic Focus CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that Cantor Fitzgerald has reiterated its Overweight rating on the Company in its latest equity research report dated November 11, 2025, while updating its 12-month price target to $31, compared to its prior target of $32.

Total Revenue Surges 568% YoY to $23.6 million ; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial results, highlighted by IM8's trajectory towards $120 million in annualized recurring revenue (“ARR”) in just 12 months by December 2025.

~ October Revenue Grew 32% MoM and on Track to hit $10 Million in Monthly Revenue by December 2025 ~ CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (Nasdaq: PRE) (“Prenetics”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced a record breaking month for IM8 in October, reaching approximately $108 million in annualized recurring revenue (ARR) just 11 months after its commercial launch.

Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity Offering Company now holds a total of 378 BTC (valued at ~$46 Million) CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announces the acquisition of 100 Bitcoin, at an average price of $109,594 per Bitcoin.

Comprehensive Document Reveals Strategic Vision Behind Company's Unprecedented Growth and Bitcoin Treasury Strategy IM8, the Fastest-Growing Supplement Brand in Industry History, Reaching Reaches $100M ARR in 11 Months Since Launch IM Projects $180-$200 Million in FY 2026 Revenue CHARLOTTE, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE (“Prenetics” or the “Company”), a leading health sciences company, today announced the publication of a comprehensive manifesto authored by CEO and Co-Founder Danny Yeung, titled "The Dual-Engine Revolution: A Manifesto for Building the Future of Health + Wealth.

CHARLOTTE, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced the closing of its previously announced best efforts public offering (the “Offering”) of (i) 2,722,642 Class A ordinary shares, par value $0.0015 per share, of the Company (the “Ordinary Shares,” the Ordinary Shares being sold in the Offering, the “Shares”), (ii) warrants of the Company to purchase up to 2,722,642 Ordinary Shares (the “Class A Common Warrants”), and (iii) warrants of the Company to purchase up to 2,722,642 Ordinary Shares (the “Class B Common Warrants” and together with the Class A Common Warrants, the “Common Warrants”) at a combined offering price of $16.08 per Share and the associated Common Warrants (the “Offering Price”).

Distinguished Investor Group Includes Kraken, American Ventures, Exodus (NYSE: EXOD), XtalPi (2228.hk), DL Holdings (1709.hk) GPTX by Jihan Wu and Leading Institutions

Dallas, Texas--(Newsfile Corp. - October 16, 2025) - Pensana PLC (LSE: PRE): Stonegate Capital Partners initiates their coverage on Pensana PLC (LSE: PRE). Pensana is one of the few developers outside China pursuing a full mine-to-magnet model, capturing value across the rare earth supply chain.

Does Prenetics Global Limited (PRE) have what it takes to be a top stock pick for momentum investors? Let's find out.